MDxHealth Past Earnings Performance

Past criteria checks 0/6

MDxHealth's earnings have been declining at an average annual rate of -4.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 41.7% per year.

Key information

-4.2%

Earnings growth rate

30.3%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate41.7%
Return on equity-246.8%
Net Margin-49.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How MDxHealth makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:MDXH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2485-426410
30 Jun 2481-41638
31 Mar 2475-40617
31 Dec 2370-43606
30 Sep 2364-45569
30 Jun 2355-48555
31 Mar 2346-47528
31 Dec 2237-44455
30 Sep 2230-40418
30 Jun 2225-34367
31 Mar 2223-31347
31 Dec 2122-29316
30 Sep 2121-28315
30 Jun 2119-28305
31 Mar 2119-28313
31 Dec 2018-29314
30 Sep 2015-36314
30 Jun 2011-43324
31 Mar 2011-43324
31 Dec 1912-43334
30 Sep 1917-37354
30 Jun 1922-31384
31 Mar 1925-32414
31 Dec 1828-32454
30 Sep 1831-30454
30 Jun 1833-28455
31 Mar 1837-20424
31 Dec 1741-12394
30 Sep 1741-9363
30 Jun 1741-5342
31 Mar 1736-9322
31 Dec 1630-13312
30 Sep 1626-15293
30 Jun 1623-17283
31 Mar 1620-16253
31 Dec 1518-14223
30 Sep 1516-14213
30 Jun 1515-13192
31 Mar 1513-14192
31 Dec 1412-15182
30 Sep 1410-16173
30 Jun 148-16163
31 Mar 148-16144
31 Dec 138-16135

Quality Earnings: MDXH is currently unprofitable.

Growing Profit Margin: MDXH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MDXH is unprofitable, and losses have increased over the past 5 years at a rate of 4.2% per year.

Accelerating Growth: Unable to compare MDXH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDXH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: MDXH has a negative Return on Equity (-246.84%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 03:54
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MDxHealth SA is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael Ruzic-GauthierBerenberg
Mark MassaroBTIG
Roderick VerhelstDegroof Petercam